Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4574793
Max Phase: Preclinical
Molecular Formula: C20H23ClFN3O
Molecular Weight: 375.88
Molecule Type: Unknown
Associated Items:
ID: ALA4574793
Max Phase: Preclinical
Molecular Formula: C20H23ClFN3O
Molecular Weight: 375.88
Molecule Type: Unknown
Associated Items:
Canonical SMILES: O=C(CCCN1CCCN(c2ccc(Cl)cn2)CC1)c1ccc(F)cc1
Standard InChI: InChI=1S/C20H23ClFN3O/c21-17-6-9-20(23-15-17)25-12-2-11-24(13-14-25)10-1-3-19(26)16-4-7-18(22)8-5-16/h4-9,15H,1-3,10-14H2
Standard InChI Key: KVGNSDMVYWRLTG-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 375.88 | Molecular Weight (Monoisotopic): 375.1514 | AlogP: 4.05 | #Rotatable Bonds: 6 |
Polar Surface Area: 36.44 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 0 |
#RO5 Violations: 0 | HBA (Lipinski): 4 | HBD (Lipinski): 0 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: | CX Basic pKa: 8.08 | CX LogP: 3.87 | CX LogD: 3.11 |
Aromatic Rings: 2 | Heavy Atoms: 26 | QED Weighted: 0.71 | Np Likeness Score: -2.25 |
1. Al-Ghanim L, Zhu XY, Asong G, Ablordeppey SY.. (2019) SYA 013 analogs as moderately selective sigma-2 (σ2) ligands: Structure-affinity relationship studies., 27 (12): [PMID:30737135] [10.1016/j.bmc.2019.01.035] |
2. Onyameh EK,Bricker BA,Eyunni SVK,Voshavar C,Gonela UM,Ofori E,Jenkins A,Ablordeppey SY. (2021) A study of the structure-affinity relationship in SYA16263; is a D receptor interaction essential for inhibition of apormorphine-induced climbing behavior in mice?, 30 [PMID:33338898] [10.1016/j.bmc.2020.115943] |
Source(1):